Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 110.55M P/E - EPS this Y 48.40% Ern Qtrly Grth -
Income -44.77M Forward P/E -2.52 EPS next Y 100.00% 50D Avg Chg -17.00%
Sales 58.2M PEG - EPS past 5Y - 200D Avg Chg -54.00%
Dividend N/A Price/Book 2.46 EPS next 5Y - 52W High Chg -88.00%
Recommedations 2.70 Quick Ratio 1.97 Shares Outstanding 52.76M 52W Low Chg 1.00%
Insider Own 10.92% ROA -19.20% Shares Float 39.15M Beta 1.68
Inst Own 54.62% ROE -109.01% Shares Shorted/Prior 3.41M/5.77M Price 2.14
Gross Margin 89.44% Profit Margin -76.93% Avg. Volume 968,046 Target Price 7.15
Oper. Margin -21.37% Earnings Date Oct 30 Volume 5,674,527 Change -2.28%
About G1 Therapeutics, Inc.

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

G1 Therapeutics, Inc. News
09/18/24 Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
09/09/24 Exploring High Growth Tech Stocks in the United States for September 2024
09/05/24 Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
08/08/24 Pharmacosmos ventures into oncology and merges with G1 Therapeutics
08/08/24 G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
08/08/24 G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
08/07/24 Top Midday Gainers
08/07/24 Pharmacosmos Group to Acquire G1 Therapeutics
08/01/24 G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/26/24 G1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutions
07/25/24 G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
07/15/24 G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
07/10/24 Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
07/01/24 G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
06/25/24 G1 Therapeutics discontinue COSELA in TNBC following Phase III flop
06/24/24 G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
06/07/24 It's Probably Less Likely That G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Will See A Huge Pay Rise This Year
05/31/24 G1 Therapeutics (NASDAQ:GTHX shareholders incur further losses as stock declines 19% this week, taking three-year losses to 84%
05/28/24 Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
04:06 PM G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
GTHX Chatroom

User Image LoveRetailFroth Posted - 1 day ago

@GunSafetyDwight @Skipper777$7 Okay I remember you. Weren’t you the guy who called me crazy doubled down to 100k on $GTHX weren’t you?

User Image LoveRetailFroth Posted - 1 day ago

$CDT $TRNR $CERO $GTHX Here is what worked for me. When you get stuck swing trading. I doubled down because the story was compelling. Don’t sell for a loss. Wait 2-3 months. DONOT Listen to these folks who either lost $$$$ & or Shorties who want you to sell when it drops. You will get your money & will make money. I am not your financial advisor. GL ☕️

User Image gthx Posted - 3 weeks ago

$GTHX thought I’d come on here one last time. Back in August when we were talking about where we were moving our BO money I mentioned that the whale I know said he was moving into VIR. It’s finally moving up and paying off. I decided instead to move into IOVA. I suppose I could have bought VIR and then sold today to move into IOVA on Monday. I think all of next week for IOVA is gonna be incredible and stupendous.

User Image LoveRetailFroth Posted - 3 weeks ago

$RR Folks called me crazy, demented liar blah blah when I bought 50k shares $GTHX after it failed Phase 3! Now who is smiling. Remember AI Robotics is hot & $NVDA relies on it supports it! This company has major deals with Walmart, MLB, etc.. Reread the SA article from 2 months ago. Great tech better financial than $SERV . Revenue will flow in & you will see $5 in no time. GL

User Image LoveRetailFroth Posted - 10/31/24

$VNDA Buyout is on the table again. Patience & will pay just like $GTHX

User Image LoveRetailFroth Posted - 10/30/24

$MIRA Reminds of $GTHX & Neutropenia drug Buyout! BIG!! 🚀

User Image Jpcarvalhinho Posted - 1 month ago

$GTHX all my other pharma stocks are climbing like crazy. :/ such a bad timing this sale.

User Image Night_Owl_Biotech Posted - 1 month ago

@Jarvis7424 @lossaversion @jonnyboi128 FWIW we get $78.6MM cash less total liabilities of $22.8 = $55.8MM in net cash @ 6/30/24. Assume 2 qtrs of $AADI cash burn at $10MM/qtr, employee & mgmt severance plus a fee to broker & we get $30MM +|- net cash (conservative) at 12/31/24 when a trnx w/b expected to close. Add A/R, Inventory + Fyarro valuation? Fyarro Peer/Comps? Q124: $RIGL paid $15MM to buy Gavreto from Blueprint + royalties/biobucks. Gavreto did $28MM in FY23 sales (Fyarro did $24MM in FY23). RIGL paid ~0.5X sales + SPPI merged w $ASRT at a $70MM EV just after Rolvedon's launch with $10MM in Q422 sales (~$40MM annualized). This was ~1.75X Rolvedon sales at the time Pharmacosmos bought $GTHX for $405MM v. $46.3MM in FY23 US Cosela sales. GTHX projected ~$150MM in FY28 sales per 14D9 filing AVEO/STML? Acquired for ~3X 1st year projected sales (but much much much bigger $ totals) Other peers/comps? We'd guess RIGL buys AADI. Only a guess. Of course we c/b wrong

User Image hnswgn Posted - 1 month ago

$MCRB $GTHX had a ‘rebuffed’ buyout rumor put out by Betaville back in May followed by a full-blown acquisition announcement in August. It resulted in a few more parties being interested and ultimately a higher final exit share price if you look at the SC 14D9 filing. Also importantly, GTHX’s rumor was one tier down from MCRB’s in terms of legitimacy. The microbiome is one of those areas in which there is expansive potential, and Seres has proven to be at the forefront with VOWST and now SER-155 showing promise. I’m as annoyed as most of you, but it was important to divest VOWST from Seres to let other suitors jump in following the readout.

User Image Jpcarvalhinho Posted - 1 month ago

$GTHX Longterm owners... where are you moving onto, after licking your wounds? I am eyeing $clnn but not that sure...

User Image StevenSeagull Posted - 2 months ago

@HenryDotDotDot @Keviin412 whoever sees this stock for anything more than an extremely risky bet, is delusional. I was ridiculed many times on $GTHX for pointing out that things could go either way before catalysts. Company sold for 7.15$ per share, turns out, some of the biggest pumpers had their avg well above that. 🤭

User Image CH_Expat Posted - 2 months ago

$GTHX $TARS $SWTX I remember how I listened to people and really trusted them when they talked about 5-10b potential BO for GTHX value. But it was a very important lesson I learned. I can only blame myself as I pulled the trigger. This was my last big loss, since then I am on the winning side. My advice: Due a lot of DD about the ones posting. Check their record, check years back. If they lose more than they win, there is no need to follow them or listen to them. This ticker here is the perfect example, the ones that are "rich" now had to average down ten times. What if you had no cash to do so and bought at 2b MC? Were you also cheering about this joke BO then?

User Image Lskynrd1 Posted - 2 months ago

$GTHX Has any1 received their earnings yet, I haven't

User Image LoveRetailFroth Posted - 2 months ago

$VNDA Good Morning ☕️ Reminds me of $GTHX 2 months ago. Failed P3 but was a great buy & eventually made a bundle when they got bought out. $300 Million in cash here. GL

User Image tilltrade Posted - 2 months ago

$GTHX https://pharmacosmos.com/news-media/news-press/pharmacosmos-group-and-g1-therapeutics-announce-successful-closing-of-tender-offer

User Image tradethehalt Posted - 2 months ago

$GTHX trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $7.14 Vol: 1.26M.

User Image tradingcalendar Posted - 2 months ago

G1 Therapeutics $GTHX tender offer from Pharmacosmos Therapeutics set to expire at midnight. - Offer to acquire GTHX shares at $7.15 for each share held - Shares of GTHX scheduled for delisting after the extended hours session More Information : https://www.sec.gov/Archives/edgar/data/1560241/000119312524216422/d851180dsc14d9a.htm

User Image Mergerbrief Posted - 2 months ago

$GTHX / Pharmacosmos A/S - Tender Offer Expires Midnight MergerBrief.com Sign Up For Full Schedule

User Image Jeffrey1977 Posted - 2 months ago

$GTHX The takeover is approved?

User Image willthethrill2 Posted - 2 months ago

$GTHX parting is such sweet sorrow!

User Image Floridahrrcn Posted - 2 months ago

$GTHX I am some shares left. What happens after merger if I don’t sell them?

User Image Backer59 Posted - 2 months ago

$GTHX IzumiSusuki....... Is there anyway to know if Pharmacosmos now has a majority of the outstanding shares that are in favor of the merger? It's hard to believe insiders & tutes like Vanguard with 2.5 million shares, think $7.15 is a good & fair offer.😎 Major Holders: 10.92% % of Shares Held by All Insider 54.28% % of Shares Held by Institutions 60.94% % of Float Held by Institutions 125 Number of Institutions Holding Shares

User Image Backer59 Posted - 2 months ago

$GTHX The IPO ... From May 16, 2017, G1, IPO anouncement.... "G1 Therapeutics today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000." There's got to be hundreds of investors both retail and institutions losing their butts with this merger. How can Pharmacosmos possibly get a majority of the outstanding shares with such losses to the shareholders?🤔😎

User Image Backer59 Posted - 2 months ago

$GTHX From....nasdaqtrader.com... "The tender offer by Pharmacosmos Therapeutics Inc. to acquire all of the outstanding common stock of G1 Therapeutics, Inc. (GTHX) is scheduled to expire one minute after 11:59 p.m. ET, on September 17, 2024, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 18, 2024. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 17, 2024. If the merger closes as planned, the stock will remain halted on the day of closing (September 18th) and will be suspended effective September 19, 2024. The details are as follows:" Company/Issue: G1 Therapeutics, Inc. Common Stock CUSIP#: 3621LQ109 Symbol: GTHX Anticipated Last Trading Date: September 17, 2024 Anticipated Marketplace Effective Date for Suspension: September 19, 2024 Merger Consideration: $7.15 for each share held.

User Image decnev Posted - 2 months ago

$GTHX What are we all thinking on the offer? I've sold off half my stake over the last few weeks at 7.14, banking 30%. I'm undecided on what to do now, take the offer on the remaining or hold! What are others planning?

User Image Jeffrey1977 Posted - 2 months ago

$GTHX I am an overseas investor, what happens if i reject. My local bank uses custodian bank in the US to purchase the shares

User Image Backer59 Posted - 2 months ago

$GTHX I've signed with NY law firm Monteverde & Assoc. They have requested info from G1, but haven't received it. By signing with them they will keep me posted on further developments if any.✔😎 https://monteverdelaw.com/

User Image Jeffrey1977 Posted - 2 months ago

$GTHX I will hold till further information. My broker says i have a dateline of 13th September to accept that offer

User Image Backer59 Posted - 2 months ago

$GTHX I read the 17 page complaint. Boils down to G1 withheld material info and misled shareholders into agreeing to the Pharmacosmos merger. NY attorney, Richard Acocelli, is asking for the merger to be postponed, for all of the withheld info to be handed over and he requests a jury trial in NY. The plaintiff is Richard Lawrence. The defendant is G1 Therapeutics Inc. including all executives and directors.👍😎

User Image joachim52 Posted - 2 months ago

$AUPH last time I saw this strength was $GTHX didn’t understand till i understood …

Analyst Ratings
Needham Hold Aug 7, 24
HC Wainwright & Co. Buy Jun 25, 24
Needham Buy Jun 25, 24
Needham Buy Jun 13, 24
HC Wainwright & Co. Buy May 28, 24
Needham Buy May 28, 24
Needham Buy May 22, 24
HC Wainwright & Co. Buy May 22, 24
HC Wainwright & Co. Buy May 2, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Umstead John W. V Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 3.06 743 2,274 130,443 01/08/24
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 03 Sell 3.06 3,740 11,444 169,938 01/08/24
Perry Andrew Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 3.12 2,413 7,529 87,102 01/08/24
Bailey John E. (Jack) Jr. President and CEO President and CEO Jan 03 Sell 3.12 11,686 36,460 489,594 01/08/24
Avagliano Mark Chief Business Offic.. Chief Business Officer Jan 03 Sell 3.06 4,081 12,488 117,834 01/08/24
MURDOCK TERRY L Chief Operating Offi.. Chief Operating Officer Jan 03 Sell 3.06 3,740 11,444 103,638 01/08/24
Bailey John E. (Jack) Jr. President and CEO President and CEO Jan 02 Sell 3.2746 32,983 108,006 400,580 01/02/24
Moses Jennifer K. CFO CFO Jan 03 Sell 5.49 2,368 13,000 57,820 01/05/23
MURDOCK TERRY L Chief Operating Offi.. Chief Operating Officer Jan 03 Sell 5.49 2,368 13,000 36,439 01/05/23
Perry Andrew Chief Commercial Off.. Chief Commercial Officer Jan 03 Sell 5.58 820 4,576 21,300 01/05/23
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 03 Sell 5.49 2,368 13,000 102,739 01/05/23
Hanson James S. General Counsel General Counsel Jan 03 Sell 5.49 2,368 13,000 41,087 01/05/23
Bailey John E. (Jack) Jr. President and CEO President and CEO Jan 03 Sell 5.72 37,626 215,221 276,282 01/05/23
Velleca Mark A. Director Director Oct 18 Sell 11.7 15,000 175,500 116,000 10/20/22
Velleca Mark A. Director Director Oct 18 Option 0.39 15,000 5,850 131,000 10/20/22
Moses Jennifer K. CFO CFO Feb 01 Option 3.95 2,333 9,215 37,888 02/02/22
Malik Rajesh Chief Medical Office.. Chief Medical Officer Feb 01 Option 0.30 10,000 3,000 73,855 02/02/22
Velleca Mark A. Director Director Apr 15 Option 0.39 30,000 11,700 51,000 04/15/21
Velleca Mark A. Director Director Apr 15 Sell 24.46 30,000 733,800 41,000 04/15/21
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 22 Option 4.17 15,000 62,550 55,200 01/22/21
Malik Rajesh Chief Medical Office.. Chief Medical Officer Jan 22 Sell 20.64 15,000 309,600 40,200 01/22/21
Velleca Mark A. Director Director Jan 21 Option 2.89 34,000 98,260 51,000 01/21/21
Velleca Mark A. Director Director Jan 21 Sell 21.01 30,000 630,300 41,000 01/21/21
RUDNICK SETH Director Director Dec 23 Sell 20.26 32,092 650,184 6,190 12/23/20
Velleca Mark A. President and CEO President and CEO Dec 17 Option 3.72 30,000 111,600 47,000 12/17/20
Velleca Mark A. President and CEO President and CEO Dec 17 Sell 19.53 30,000 585,900 37,000 12/17/20
RUDNICK SETH Director Director Dec 10 Sell 20.17 19,480 392,912 38,282 12/10/20
Bailey John E. (Jack) Jr. Director Director Nov 13 Buy 12.8 8,000 102,400 8,000 11/13/20